Are Hormonal Agents Better Than Chemo in Metastatic Castration-resistant Prostate Cancer?

OBJECTIVE In this study, we aim to determine which treatment is more appropriate in castration-resistant chemotherapy- naive patients. Therefore, docetaxel and agents active in the androgen pathway (abiraterone and enzalutamide) were compared retrospectively in patients progressing on androgen deprivation therapy. METHODS The study was designed as a retrospective and multicenter study. Patients from five centers in Turkey were included in the study. The primary endpoint of the study was overall survival (OS) and the secondary endpoint was progression-free survival. RESULTS Median OS of the docetaxel group was 18.66 months, it was 16.26 months in the hormonal treatment group. There was no statistically significant difference between the groups (p=0.311). Median progressionfree survival of the chemotherapy group was 5.6 months, while it was 9 months in the hormonal therapy group. There was statistically significant difference between the groups (p=0.024). CONCLUSION There was statistical difference in progression-free survival in favor of hormonal therapies in our study. The difference did not reflect on OS and there was no difference between hormonal therapies and docetaxel. Heterogeneity in the selection of patients is considered to lead to this result; however, larger randomized controlled studies are needed to determine the most appropriate treatment in these patients.

PDF

___

1. Huggins C, Stevens RE Jr., Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209–23.
2. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007;13(21):6396–403.
3. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010;46(3):517–25.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12.
5. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534–40.
6. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Fléchon A, Skoneczna I, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomized trial. Lancet Oncol 2013;14(8):760–8.
7. Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy- naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomized, doubleblind, placebo-controlled phase 3 trial. Lancet Oncol 2015;16(4):417–25.
8. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomized, double-blind phase 3 trial. Lancet Oncol 2013;14(13):1307–16.
9. Quinn DI, Tangen CM, Hussain M, Lara PN Jr., Goldkorn A, Moinpour CM, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomized phase 3 trial. Lancet Oncol 2013;14(9):893–900.
10. Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2013;31(14):1740–7.
11. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011;29(16):2191–8.
12. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, et al. Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 2006;12(20 Pt):6094–9.
13. Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 2006;107(4):738–45.
14. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology 2007;69(1):142–6.
15. Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, et al. Cabazitaxel versus docetaxel as firstline therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III Trial- FIRSTANA. J Clin Oncol 2017;35(28):3189–97.
16. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014;66(5):815–25.
17. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone chemotherapynaive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomized, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015;16(2):152–60.
18. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48.
19. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33.
20. Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): Results from a randomized, phase 3trial. Lancet Oncol 2015;16(5):509–21.
21. Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, et al. The PREVAIL study: Primary outcomes by site and extent of baseline disease for enzalutamide- treated men with chemotherapy-naïve metastatic castration-resistant prostate cancer. Eur Urol 2016;70(4):675–83.